(Q36305432)

13 August 2017

title

Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan (English)

1 reference

13 August 2017

1 reference

Maki Ando

1

1 reference

13 August 2017

Yoshinori Hasegawa

series ordinal

2

1 reference

13 August 2017

Yuichi Ando

series ordinal

3

1 reference

13 August 2017

publication date

1 December 2005

1 reference

Investigational New Drugs

13 August 2017

published in

1 reference

13 August 2017

volume

23

1 reference

13 August 2017

issue

6

1 reference

13 August 2017

page(s)

539-545

1 reference

Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation

13 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-005-4022-6

Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-005-4022-6

Effects of St. John's wort on irinotecan metabolism

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-005-4022-6

UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer

21 January 2018

1 reference

12 December 2020

Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

1 reference

12 December 2020

Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes

1 reference

12 December 2020

Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials

1 reference

12 December 2020

Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.

1 reference

12 December 2020

Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

1 reference

12 December 2020

Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus

1 reference

12 December 2020

A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini

1 reference

12 December 2020

Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia

1 reference

12 December 2020

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese

1 reference

12 December 2020

UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan

1 reference

12 December 2020

Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome

1 reference

12 December 2020

Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports

1 reference

12 December 2020

The UGT1A1*28 allele is relatively rare in a Japanese population

1 reference

12 December 2020

Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes

1 reference

12 December 2020

Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.

1 reference

12 December 2020

Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.

1 reference

12 December 2020

Irinotecan therapy in adults with recurrent or progressive malignant glioma

1 reference

12 December 2020

Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients

1 reference

12 December 2020

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

1 reference

12 December 2020

Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity

1 reference

12 December 2020

Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.

1 reference

12 December 2020

Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea

1 reference

12 December 2020

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer

1 reference

12 December 2020

Irinotecan pathway genotype analysis to predict pharmacokinetics

1 reference

12 December 2020

Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin

1 reference

12 December 2020

Irinotecan in small-cell lung cancer.

1 reference

12 December 2020

Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).

1 reference

12 December 2020

Pharmacogenetics and the practice of medicine

1 reference

12 December 2020

Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism

1 reference

12 December 2020

Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

1 reference

12 December 2020

Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients

1 reference

12 December 2020

In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9.

1 reference

12 December 2020

Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver

1 reference

12 December 2020

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

1 reference

12 December 2020

The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence

1 reference

12 December 2020

ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition

1 reference

12 December 2020

Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion

1 reference

12 December 2020

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

1 reference

12 December 2020

Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer

1 reference

12 December 2020

The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome

1 reference

12 December 2020

10.1007/S10637-005-4022-6

Identifiers

DOI

1 reference

13 August 2017

1 reference